Elvinix is a biotechnology company developing a scalable regenerative therapy for type 1 diabetes.
Elvinix was founded to translate more than three decades of β-cell regeneration research into a practical, scalable therapy for T1D. The company brings together the foundational science of Dr Alex Rabinovitch, the clinical and translational insight of Dr Jay Skyler, the regulatory expertise of Dr Zan Fleming, a peptide platform developed by Zealand Pharma, proprietary Elvinix innovation including combinatorial IP, and a multidisciplinary team with experience across T1D biology, regulatory strategy and pharmaceutical development.
“Type 1 diabetes has been managed for more than a century by replacing insulin. We’ve licensed Zealand’s dual-agonist peptide platform, backed by years of rigorous preclinical work, brought together a remarkable team and identified what we believe is the missing piece of the puzzle. Patients have waited a long time for a treatment that can change the course of this disease, and our mission is to deliver one.”
Daniil Koshelev
Chief Executive Officer and Co-founder
“Our earlier findings revealed that gastrin directs a key pathway in the normal embryonic development of β-cells, and that gastrin can transform pancreatic exocrine duct cells into insulin-secreting β-like cells in vitro and in vivo. We believe this action of gastrin can be applied to restore β-cell mass and insulin secretion in patients with type 1 diabetes. Our work at Elvinix has since uncovered new and vital mechanisms that support this process, advancing this science toward a real treatment for type 1 diabetes.”
Dr Alex Rabinovitch
Co-founder and Senior Scientific Advisor
“A safe, accessible, and affordable means of reversing type 1 diabetes has been one of the great unmet goals of modern medicine and my career long focus. I am encouraged by the substantial and growing body of evidence supporting the potential of Elvinix to restore insulin secretion and thereby transform the lives of people living with type 1 diabetes.”
G. Alexander “Zan” Fleming, MD
Co-founder and Board Director
Elvinix combines exclusive licensed rights with an expanding portfolio of company-owned intellectual property. The program is being advanced with experienced scientific, clinical, regulatory, pharmaceutical and legal advisors, creating a foundation for future financing and strategic collaboration.